Updated on: September 8, 2022
BCCDC Clinical Guidance Document updated as follows: Under the Severely Ill section – Baricitinib information added to the immunomodulatory therapy section, under Mildly Ill – Monoclonal antibodies replaced Sotrovimab content.
Information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information.